Safety and acceptability of the 52 mg levonorgestrel-releasing intrauterine system in women with abnormal uterine bleeding in an ambulatory care center in Bogotá, Colombia, 2012-2016
DOI:
https://doi.org/10.18597/rcog.3547Abstract
Objective: To describe safety and acceptability with the use of the 52-mg levonorgestrel-releasing intrauterine system in women with abnormal uterine bleeding. Materials and methods: Retrospective cohort of women 18 years of age and older diagnosed with abnormal uterine bleeding, ultrasound-reported uterine length between 6 and 10 cm and uniform endometrial cavity in its entire length, regardless of structural abnormality, who received treatment with 52-mg levonorgestrel-releasing intrauterine system between 2012 and 2016. Non-probabilistic convenience sampling was carried out. Sociodemographic and clinical baseline variables were measured, as well as patient perception of bleeding and the frequency of failure, amenorrhea, need for hysterectomy and adverse events, over a 12-month follow-up period. Descriptive statistics were applied. Results: Overall, 200 patients were assessed. A subjective perception of improvement in terms of bleeding volume and frequency of leave of absence or visits to the emergency department was found; 90% of the patients had amenorrhea, and 6% experienced adverse events. Conclusions: The 52-mg levonorgestrel-releasing intrauterine system is a safe option for the management of abnormal uterine bleeding in women with normal uterine size and no submucosal endometrial abnormalities. Local randomized studies are required to assess effectiveness and efficiency in comparison with other management options.
References
Munro MG, Critchley HOD, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113(1):3-13. https://doi.org/10.1016/j.ijgo.2010.11.011
Munro MG, Critchley HOD, Fraser IS, Haththotuwa R, Kriplani A, Bahamondes L, et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet. 2018;143(3):393-408. https://doi.org/10.1002/ijgo.12666
Spencer CP, Whitehead MI. Endometrial asessment re-visited. Br J Obstet Gynaecol. 1999;106(7):623-32. https://doi.org/10.1111/j.1471-0528.1999.tb08358.x
Fraser IS, Critchley HOD, Munro MG, Broder M. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril. 2007;87(3):466-76. https://doi.org/10.1016/j.fertnstert.2007.01.023
Fraser IS, Critchley HOD, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007;22(3):635-43. https://doi.org/10.1093/humrep/del478
Munro MG, Critchley HOD, Fraser IS. Research and clinical management for women with abnormal uterine bleeding in the reproductive years: More than PALM-COEIN. Br J Obstet Gynaecol. 2017;124(2):185-9. https://doi.org/10.1111/1471-0528.14431
National Institute for Health and Care Excellence (NICE). Heavy menstrual bleeding: Assessment and management. NG88; March 2018. Disponible en: https://www.nice.org.uk/guidance/ng88.
Xiao B, Wu S-C, Chong J, Zeng T, Han L-H, Luukkainen T. Therapeutic effects of the levonorgestrelreleasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril. 2003;79(4):963-9. https://doi.org/10.1016/s0015-0282(02)04913-0
Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: A randomized controlled trial. Obstet Gynecol. 2006;108(4):924-9. https://doi.org/10.1097/01.AOG.0000238343.62063.22
James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: Consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):124-34. https://doi.org/10.1016/j.ejogrb.2011.04.025
Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2019;9:CD000400. https://doi.org/10.1002/14651858.CD000400.pub4
ACOG. Committee opinion: Management of acute AUB in nonpregnant re-productive aged women. Obstet Gynecol. 2014;123(603):1403-7.
Bayer AG, Berlin G. Mirena Annotated CCDS 2014; 2014.
Phillips V, Graham CT, Manek S, McCluggage WG. The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. J Clin Pathol. 2003;56(4):305-7. https://doi.org/10.1136/jcp.56.4.305
Bayer HealthCare Pharmaceuticals Inc. Mirena® (levonorgestrel- releasing intrauterine system) prescribing information. 2014;1-193.
Beatty MN, Blumenthal PD. The levonorgestrelreleasing intrauterine system: Safety, efficacy, and patient acceptability. Ther Clin Risk Manag. 2009/08/03. 2009;5(1):561-74. https://doi.org/10.2147/tcrm.s5624
Bofill Rodriguez M, Lethaby A, Jordan V. Progestogenreleasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2020;6:CD002126. https://doi.org/10.1002/14651858.CD002126.pub4
Espey E. Levonorgestrel intrauterine system—firstline therapy for heavy menstrual bleeding. N Engl J Med. 2013;368(2):184-5. https://doi.org/10.1056/NEJMe1214191
Benetti-Pinto CL, De Sá Rosa-E-Silva ACJ, Yela DA, Júnior JMS. Sangramento uterino anormal. Rev Bras Ginecol Obstet. 2017;39(7):358-68. https://doi.org/10.1055/s-0037-1603807
Yuk JS, Song JY, Lee JH, Park WI, Ahn HS, Kim HJ. Levonorgestrel-Releasing Intrauterine Systems versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A meta-analysis. Ann Surg Oncol. 2017;24(5):1322-9. https://doi.org/10.1245/s10434-016-5699-9.
Food and Drug Administration (FDA). Center for Drug evaluation and research. Application number: NDA 021225 S-031.
Costescu DJ. Levonorgestrel-releasing intrauterine systems for long-acting contraception: Current perspectives, safety, and patient counseling. Int J Womens Health. 2016;8:589-598. https://doi.org/10.2147/IJWH.S9970522.
d’Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception. 2007;75(6 Suppl):S2-7. https://doi.org/10.1016/j.contraception.2006.12.024
Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril. 2003; 79(5):1194-8. https://doi.org/10.1016/S0015-0282(03)00175-4.
Magalhães J, Aldrighi JM, de Lima GR. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. Contraception. 2007;75(3):193-8. https://doi.org/10.1016/j.contraception.2006.11.004
Murat Naki M, Tekcan C, Ozcan N, Cebi M. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes. Fertil Steril. 2010;94(1):371-4. https://doi.org/10.1016/j.fertnstert.2009.09.048
Gunes M, Ozdegirmenci O, Kayikcioglu F, Haberal A, Kaplan M. The Effect of Levonorgestrel Intrauterine System on Uterine Myomas: A 1-Year Follow-up Study. J Minim Invasive Gynecol. 2008;15(6):735-8. https://doi.org/10.1016/j.jmig.2008.08.011
Ozdegirmenci O, Kayikcioglu F, Akgul MA, Kaplan M, Karcaaltincaba M, Haberal A, et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril. 2011;95(2):497-502. https://doi.org/10.1016/j.fertnstert.2010.10.009
Heikinheimo O, Gemzell-Danielsson K. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS). Acta Obstet Gynecol Scand. 2012;91(1):3-9. https://doi.org/10.1111/j.1600-0412.2011.01303.x
Desai R. Efficacy of levonorgestrel releasing intrauterine system for the treatment of menorrhagia due to benign uterine lesions in perimenopausal women. J Midlife Health. 2012;3(1):20. https://doi.org/10.4103/0976-7800.98812
Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. Br Med J. 1998;316(7138):1122-6. https://doi.org/10.1136/bmj.316.7138.1122
Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2003;(2):CD003855. https://doi.org/10.1002/14651858.cd003855
Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivelä A, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: Randomized trial 5-year follow-up. J Am Med Assoc. 2004;291(12):1456-63. https://doi.org/10.1001/jama.291.12.1456
Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol. 1991;164(3):879-83. https://doi.org/10.1016/S0002-9378(11)90533-X
Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. A canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Canada. 2009;31(4):340-7. https://doi.org/10.1016/S1701-2163(16)34151-2
Marions L, Lövkvist L, Taube A, Johansson M, Dalvik H, Øverlie I. Use of the levonorgestrel releasingintrauterine system in nulliparous women—a noninterventional study in Sweden. Eur J Contracept Reprod Heal Care. 2011;16(2):126-34. https://doi.org/10.3109/13625187.2011.558222
Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J. The levonorgestrel-releasing intrauterine system in human immunodeficiency virusinfected women: Z 5-year follow-up study. Am J Obstet Gynecol. 2011;204(2):126.e1-126.e4. https://doi.org/10.1016/j.ajog.2010.09.002
Rogovskaya S, Rivera R, Grimes DA, Chen PL, Pierre-Louis B, Prilepskaya V, et al. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: A randomized trial. Obstet Gynecol. 2005;105(4):811-5. https://doi.org/10.1097/01.AOG.0000156301.11939.56
Lukes AS, Reardon B, Arepally G. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril. 2008;90(3):673-7. https://doi.org/10.1016/j.fertnstert.2007.07.1315
How to Cite
Downloads
Downloads
Published
Issue
Section
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |